We allow the width of the electron beam and the width of the grating to vary independently
and require the walls to be high compared to the wavelength of the evanescent wave. The results show that the side walls change the empty-grating dispersion click here relation in important ways. When the separation of the walls is not too large, it is sufficient to consider only the lowest-order transverse mode of the grating. In this case, we obtain excellent agreement with numerical simulations and experimental results.”
“Objective: To identify patients at high risk of relapse after anti-tuberculosis (TB) therapy or with poor long-term outcomes.
Methods: Fifty-one patients with pulmonary TB: 7 were classified as high association with both cavitations on initial chest radiography and positive sputum smear/cultures after two months of anti-TB treatment (HA group); 19 medium association (MA, one risk alone); and 25 low association (LA, neither risk). Serum interferon (IFN)-gamma-inducible selleck compound protein 10 (IP-10), interleukin-17 (IL-17), and C-reactive protein levels were investigated.
Results: There was a trend towards higher serum IP-10 levels (p = 0.042) for HA patients throughout the 6-month
treatment period. Month-2 IP-10 levels were higher in the HA than in the MA/LA group (656.2 +/- 234.4 vs. 307.6 +/- 258.5 pg/ml, adjusted p = 0.005). Receiver operating characteristic curves showed that the risk of relapse was well-captured by month-2 IP-10 levels at a cut-off value of 431 pg/ml (AUC = 0.857, 95% CI 0.75-0.97, p = 0.003). Month-2 serum IL-17 levels were lower in non-survivors than survivors (15.7 +/- 2.9 pg/ml vs. 24.6 +/- 8.2 pg/ml, p = 0.001). Multivariate analysis demonstrated that a month-2 serum IL-17 level of <= 17 pg/ml (p = 0.026) was independently associated with all-cause mortality.
Conclusions: Serum IP-10 and IL-17 levels after 2 months of anti-TB treatment
may be biomarkers for estimating risk of both cavitation and delayed sputum conversion, and for predicting long-term mortality, respectively.”
“Since its inception, ISEMIR has held an annual education meeting highlighting the changes in the utilization of this website imaging tools for the management of rheumatic diseases. ISEMIR’s international faculty and world-renowned experts have discussed these topics at a very high scientific level. The evolution of the content demonstrates the rapidly changing environment in the field of rheumatology. Advances in treatment have led to the increased use of magnetic resonance imaging (MRI) and ultrasound (US). This publication is based upon the proceedings from the 2012 ISEMIR educational meeting that took place on April 26th in Chicago, Illinois. Presentations from the live proceedings can be viewed at www.isemir.org. (c) 2012 Elsevier Inc. All rights reserved.